Patent ID: 8618157
Filing Date: 2013-12-31
Classification: A61K,A61P

Abstract:
1. A pharmaceutical composition comprising: a. a 5-HT1 agonist selected from the group consisting of a triptan, ergotamine, 5carboxamidotryptamine, 3-[(N-2-methoxyethyl) pyrrolidine-2R-ylmethyl]-5-(2-oxo-1,3-oxazolidin-4S-ylmethyl)-1H-indole, 5-(2-oxo-1,3-oxazolidin-4S-ylmethyl)-3-(pyrrolidine-2R-ylmethyl-1H-indole, 3-[N-methylpyrrolidine-2R-ylmethyl]-5-(2-oxo-1,3-oxazolidin-4R,S-ylmethyl)-1H-indole, and pharmaceutically acceptable salts thereof; b. a non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of acidic NSAIDs, long acting NSAIDs, and COX-2 inhibitors; and c. a disintegrant, wherein the disintegrant is cross-linked polyvinylpyrrolidone, hydroxypropylcellulose, low substituted hydroxypropylcellulose, carboxymethylcellulose calcium, carboxymethylcellulose sodium, sodium starch glycollate, docusate sodium, pregelatinized starch, colloidal silicon dioxide, sodium citrate, polyethylene glycol, polyoxyethylene, magnesium carbonate, calcium carbonate or sodium bicarbonate, wherein the 5-HT1 agonist and the NSAID are present in the pharmaceutical composition in a single phase, the disintegrant comprises between about 15 to about 50% w/w based on the weight of the composition, and said composition optionally comprises one or more other pharmaceutically acceptable excipients.